Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Insmed (NASDAQ:INSM) and raises the price target from $42 to $75.
June 21, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Insmed and raises the price target from $42 to $75.
The raised price target from $42 to $75 by a reputable analyst at Evercore ISI Group is a strong positive signal for investors. The Outperform rating suggests confidence in the company's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100